Open AccessAnalysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab
Author(s) -
Dominika WcisłoDziadecka,
Beniamin Oskar Grabarek,
Celina KruszniewskaRajs,
Joanna Gola,
Klaudia Simka,
Urszula Mazurek
Publication year - 2020
Publication title -
advances in clinical and experimental medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.486
H-Index - 27
eISSN - 2451-2680
pISSN - 1899-5276
DOI - 10.17219/acem/112607
Subject(s) - ustekinumab , medicine , psoriasis , psoriasis area and severity index , dermatology life quality index , tumor necrosis factor alpha , interleukin 23 , gastroenterology , tumor necrosis factor receptor 1 , statistical significance , interleukin , immunology , oncology , adalimumab , cytokine , tumor necrosis factor receptor
Ustekinumab is a monoclonal antibody that shows the ability to bind to subunit p40, common for interleukin 12 (IL-12) and IL-23, which prevents the activation of the JAK STAT signaling pathway.